|
Sections |
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents
The Top 10 Pharmaceutical Companies in India Executive summary 12
Industry overview 12
Cipla 13
Ranbaxy 13
GSK (India) 14
Piramal Healthcare 14
Zydus Cadila 15
Sun Pharma 15
Lupin Laboratories (Lupin) 16
Alkem 16
Sanofi-Aventis (India) 17 | 0 | 1 |
| Table of Contents | 0 | 1 |
| The Top 10 Pharmaceutical Companies in India Executive summary 12 | 0 | 1 |
| Industry overview 12 | 0 | 1 |
| Cipla 13 | 0 | 1 |
| Ranbaxy 13 | 0 | 1 |
| GSK (India) 14 | 0 | 1 |
| Piramal Healthcare 14 | 0 | 1 |
| Zydus Cadila 15 | 0 | 1 |
| Sun Pharma 15 | 0 | 1 |
| Lupin Laboratories (Lupin) 16 | 0 | 1 |
| Alkem 16 | 0 | 1 |
| Sanofi-Aventis (India) 17 | 0 | 1 |
| Mankind Pharma (Mankind) 17 | 0 | 1 |
| Chapter 1 Introduction 20 | 0 | 1 |
| What is this report about? 20 | 0 | 1 |
| Methodology 20 | 0 | 1 |
| Chapter 2 Industry overview 24 | 0 | 1 |
| Summary 24 | 0 | 1 |
| Introduction 25 | 0 | 1 |
| Market dynamics 25 | 0 | 1 |
| Indian pharmaceutical market: size and growth 25 | 0 | 1 |
| Key market drivers and resistors 26 | 0 | 1 |
| India’s adoption of product patent regime 27 | 0 | 1 |
| Evolution of biopharmaceuticals in India 28 | 0 | 1 |
| Competitive positioning of India in global pharmaceutical market 30 | 0 | 1 |
| Competitive landscape 32 | 0 | 1 |
| Competitive positioning of the top 10 companies 32 | 0 | 1 |
| Exposure to US generics market 35 | 0 | 1 |
| Comparative analysis of the top 10 companies 36 | 0 | 1 |
| Trends 37 | 0 | 1 |
| Increasing participation of innovator companies in Indian pharmaceutical space 37 | 0 | 1 |
| Pharmaceutical companies making inroads into rural India 38 | 0 | 1 |
| Shifting focus towards Japanese generics market 39 | 0 | 1 |
| Growing prevalence of lifestyle diseases 40 | 0 | 1 |
| Expanding alliances in biopharmaceuticals 41 | 0 | 1 |
| Chapter 3 Cipla 46 | 0 | 1 |
| Summary 46 | 0 | 1 |
| Company overview 47 | 0 | 1 |
| Marketed products 47 | 0 | 1 |
| Therapeutic focus 49 | 0 | 1 |
| Research and development 49 | 0 | 1 |
| Growth strategies 50 | 0 | 1 |
| Expanding in international markets through alliances and partnerships 50 | 0 | 1 |
| Expanding capabilities 50 | 0 | 1 |
| Growing in the US generics market 51 | 0 | 1 |
| Acquisitions and divestments 51 | 0 | 1 |
| SWOT analysis 52 | 0 | 1 |
| Chapter 4 Ranbaxy 54 | 0 | 1 |
| Summary 54 | 0 | 1 |
| Company overview 55 | 0 | 1 |
| Marketed products 56 | 0 | 1 |
| Therapeutic focus 56 | 0 | 1 |
| Research and development 57 | 0 | 1 |
| Growth strategies 58 | 0 | 1 |
| Rebuilding business in the US market 58 | 0 | 1 |
| Shifting focus towards complex products in the US 58 | 0 | 1 |
| Monetizing the FTF opportunities in the US 58 | 0 | 1 |
| Improving penetration in emerging markets 59 | 0 | 1 |
| Strengthening management involvement in Ranbaxy 59 | 0 | 1 |
| Acquisitions and divestments 60 | 0 | 1 |
| SWOT analysis 61 | 0 | 1 |
| Chapter 5 GSK (India) 64 | 0 | 1 |
| Summary 64 | 0 | 1 |
| Company overview 65 | 0 | 1 |
| Marketed products 66 | 0 | 1 |
| Therapeutic focus 66 | 0 | 1 |
| Research and development 67 | 0 | 1 |
| Growth strategies 68 | 0 | 1 |
| Augmenting product portfolio in India 68 | 0 | 1 |
| Leveraging its parent company’s product portfolio 68 | 0 | 1 |
| In-licensing products 69 | 0 | 1 |
| Expanding rural presence and hospital sales 69 | 0 | 1 |
| Acquisitions and divestments 70 | 0 | 1 |
| SWOT analysis 71 | 0 | 1 |
| Chapter 6 Piramal Healthcare 74 | 0 | 1 |
| Summary 74 | 0 | 1 |
| Company overview 75 | 0 | 1 |
| Marketed products 75 | 0 | 1 |
| Therapeutic focus 77 | 0 | 1 |
| Research and development 77 | 0 | 1 |
| Growth strategies 78 | 0 | 1 |
| Capitalize on contract manufacturing opportunities 78 | 0 | 1 |
| Growing business through alliances and partnerships 78 | 0 | 1 |
| Acquisitions and divestments 79 | 0 | 1 |
| SWOT analysis 81 | 0 | 1 |
| Chapter 7 Zydus Cadila 84 | 0 | 1 |
| Summary 84 | 0 | 1 |
| Company overview 85 | 0 | 1 |
| Marketed products 86 | 0 | 1 |
| Therapeutic focus 86 | 0 | 1 |
| Research and development 87 | 0 | 1 |
| Growth strategies 88 | 0 | 1 |
| Alliances fostering growth in international generics markets 88 | 0 | 1 |
| Sustaining revenue growth in Indian formulation business 89 | 0 | 1 |
| v | 0 | 1 |
| Acquisitions and divestments 90 | 0 | 1 |
| SWOT analysis 91 | 0 | 1 |
| Chapter 8 Sun Pharma 94 | 0 | 1 |
| Summary 94 | 0 | 1 |
| Company overview 95 | 0 | 1 |
| Marketed products 95 | 0 | 1 |
| Therapeutic focus 97 | 0 | 1 |
| Research and development 97 | 0 | 1 |
| Growth strategies 98 | 0 | 1 |
| Enhancing presence in the US market 98 | 0 | 1 |
| Focusing on niche segments in developing markets 98 | 0 | 1 |
| Plugging gaps in its business through investments 99 | 0 | 1 |
| Acquisitions and divestments 99 | 0 | 1 |
| SWOT analysis 100 | 0 | 1 |
| Chapter 9 Lupin 102 | 0 | 1 |
| Summary 102 | 0 | 1 |
| Company overview 103 | 0 | 1 |
| Marketed products 103 | 0 | 1 |
| Therapeutic focus 104 | 0 | 1 |
| Research and development 104 | 0 | 1 |
| Growth strategies 105 | 0 | 1 |
| Expanding in European markets 105 | 0 | 1 |
| Foray into biosimilars market 105 | 0 | 1 |
| Sustaining growth in the US generics market 106 | 0 | 1 |
| Shifting focus to chronic and specialized products in India 106 | 0 | 1 |
| Acquisitions and divestments 106 | 0 | 1 |
| SWOT analysis 108 | 0 | 1 |
| Chapter 10 Alkem 110 | 0 | 1 |
| Summary 110 | 0 | 1 |
| Company overview 111 | 0 | 1 |
| Marketed products 111 | 0 | 1 |
| Therapeutic focus 112 | 0 | 1 |
| Research and development 112 | 0 | 1 |
| Growth strategies 113
Expanding presence in nutraceuticals business 113
Expansion in international markets 113
Acquisitions and divestments 114
SWOT analysis 114
Chapter 11 Sanofi-Aventis (India) 116
Summary 116
Company overview 117
Marketed products 117
T | 0 | 1 |
